NCT04653142已完成1 期
An Open Label, Phase I Study of BI 765063 Monotherapy, and Its Combination Therapy With BI 754091, to Characterize Safety, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 4
- 主要终点
- Maximum Tolerated Dose (MTD) of BI 765063, Part A
研究概览
简要总结
This study is open to Japanese adults with advanced cancer (solid tumors). This is a study in people for whom previous treatment was not successful and for whom no standard therapy exists. The purpose of this study is to find the highest dose of BI 765063 that people can tolerate when taken alone or together with a medicine called BI 754091. BI 765063 and BI 754091 are antibodies that may help the immune system fight cancer (checkpoint inhibitors).
Participants get BI 765063 alone or together with BI 754091 as infusion every 3 weeks.
Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors check the health of the participants and note any health problems that could have been caused by BI 765063 or BI 754091.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated the written informed consent form (ICF) prior to any trial-specific procedures
- •Male or female aged ≥ 20 years (no upper limit of age) at the time of ICF signature
- •Patients who were born in Japan, and have lived outside Japan <10 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the screening visit
- •Life expectancy of at least 3 months
- •Patients with at least one Signal Regulatory Protein-alpha (SIRPα) V1 allele will be selected, i.e. homozygous V1/V1 or heterozygous V1/V2; SIRPα polymorphism will be assessed in blood sampling (patient DNA); V1 allele is understood to include V1 and V1-like alleles
- •Patients with histologically or cytologically documented advanced/metastatic primary or recurrent solid tumors who failed or are not eligible to standard therapy
- •Patients with at least one measurable lesion as per RECIST v1.1 Further inclusion criteria apply.
排除标准
- •Patients without at least one SIRPα V1 allele, i.e. SIRPα V2/V2 individuals
- •Previous treatment with study medications in this trial
- •Patients with symptomatic/active central nervous system (CNS) metastases. Patients with previously treated brain metastases are eligible, if there is no evidence of progression for at least 28 days before the first study drug administration without requirement for treatment with corticosteroids, as ascertained by clinical examination and brain imaging magnetic resonance imaging (MRI) or computed tomography (CT)) during the screening period
- •Any tumor location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery or radiation therapy, such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture)
- •Presence of active invasive cancers other than the one treated in this trial within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment
- •Patients with active autoimmune disease or a documented history of autoimmune disease, that requires systemic treatment, i.e. corticosteroids or immunosuppressive drugs, except patients with vitiligo, resolved childhood asthma/atopy, alopecia, or any chronic skin condition that does not require systemic therapy, patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and/or controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible
- •Patients who has experienced severe infusion related reaction (IRR) to monoclonal antibody (mAb) (Grade ≥ 3 NCI CTCAE v5.0)
- •Patients removed from previous anti-PD-1 or anti-PD-L1 therapy because of a severe, or life-threatening immune related adverse event (irAE) (Grade ≥ 3 NCI CTCAE v5.0) Further exclusion criteria apply.
研究组 & 干预措施
BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)
Experimental
干预措施: BI 765063 (Drug)
BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)
Experimental
干预措施: BI 754091 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) of BI 765063, Part A
时间窗: up to 3 weeks
Maximum Tolerated Dose (MTD) of BI 765063, Part B
时间窗: up to 3 weeks
Number of patients with dose limiting toxicity (DLT) in the MTD evaluation period, Part B
时间窗: up to 3 weeks
Number of patients with dose limiting toxicity (DLT) in the MTD evaluation period, Part A
时间窗: up to 3 weeks
次要结局
- Percentage of patients with drug related Adverse Events (AE), Part B(3 weeks per treatment cycle)
- Number of patients with DLTs, Part A(3 weeks per treatment cycle)
- Number of patients with DLTs, Part B(3 weeks per treatment cycle)
- Percentage of patients with drug related Adverse Events (AE), Part A(3 weeks per treatment cycle)
- AUC0-tz (area under the curve) for BI 765063, Part B(up to 3 weeks)
- Cmax (maximum concentration) for BI 765063, Part A(up to 3 weeks)
- Cmax (maximum concentration) for BI 765063, Part B(up to 3 weeks)
- Cmax (maximum concentration) for BI 754091, Part B(up to 3 weeks)
- AUC0-tz (area under the curve) for BI 765063, Part A(up to 3 weeks)
- AUC0-tz (area under the curve) for BI 754091, Part B(up to 3 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)Solid Tumors, KRAS MutationNCT04742556Boehringer Ingelheim15
进行中（未招募）
1 期
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerNCT04958239Boehringer Ingelheim151
已完成
1 期
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJPart 1- Advanced Solid TumorsPart 2- Advanced or Metastatic Gastric CancerPart 2- Advanced or Metastatic GEJNCT01791374Amgen21
已完成
1 期
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid TumorsAdvanced Solid TumorsNCT03934359Shanghai De Novo Pharmatech Co., Ltd.19
已完成
1 期
BI 894999 First in Human Dose Finding Study in Advanced MalignanciesNeoplasmsNUT CarcinomaNCT02516553Boehringer Ingelheim174